TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01654263

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Description: Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
Study: NCT02504047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: T-Cell replete haplo-transplant
Description: Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 \& 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
Study: NCT01340742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Pre-conditioning
Description: Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Cuff placed on arm uninflated for 30 minutes.
Study: NCT04233437

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC1501
Description: MLC1501 capsules (4 capcules (2000 mg) twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC1501
Description: MLC1501 capsules (4 capcules (2000 mg) twice a day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CYP Cocktail
Description: Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transporter Cocktail
Description: Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg
Study: NCT03638830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim
Description: Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)+placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ftortiazinon (tablets 300 mg) full dose + Maxipim
Description: Ftortiazinon tablets 300 mg (FSBI N.F. Gamaleya NRCEM of the Ministry of Health of the Russian Federation)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo+Maxipim
Description: placebo
Study: NCT01808222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FACBC
Description: Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).
Study: NCT02469012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #1
Description: Sofosbuvir + Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #2
Description: Sofosbuvir + Daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #3
Description: Sofosbuvir + Daclatasvir + Ribavirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #4
Description: Sofosbuvir + Ledipasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination #5
Description: Sofosbuvir + Ledipasvir + Ribavirin
Study: NCT04161105

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling is an invasive procedure involving inserting acupuncture needles directly into trigger points within muscles. The needle is partially withdrawn and re-inserted repeatedly to maximally stimulate the muscle and it's fibers.
Study: NCT04384198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sonolysis
Description: Continuous transcranial Doppler sonography (TCD) using a 2-MHz diagnostic probe with maximal diagnostic energy
Study: NCT02900664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PDR001
Description: Powder for solution for infusion
Study: NCT00004251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: 2.5 mg of letrozole per day
Study: NCT02296216

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gamma Knife radiosurgery
Description: To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
Study: NCT04709159

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Call for Life Uganda
Description: Call for Life™ Uganda (C4LU) is a web-based mHealth tool that provides treatment support to patients in the form of daily or weekly pill adherence reminders, health messages, clinic appointment reminders and a remote symptom reporting service. The tool interacts with patients by text message (SMS) or using voice and tone input via keypad (Interactive Voice Response - IVR) on both analogue and smart phones.~The tool uses CONNECT FOR LIFE technology, which is on an open source platform developed by Grameen Foundation and the University of Southern Maine with financial support from the Bill and Melinda Gates Foundation. It was supported by Janssen, the Pharmaceutical Companies of Johnson and Johnson and was released under the terms of the MOTECH open source license agreement.
Study: NCT02975089

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-nutrient supplement
Description: 1. 1.3g/d multivitamins \& minerals powder~2. Leaflet content (same as control)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multi-nutrient & soy protein supplement
Description: 1. 1.3g/d multivitamins \& minerals powder~2. 16g/d isolated soy protein powder~3. Leaflet content (same as control)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition education on balanced diet & food supplement
Description: 1. Nutrition education with a designed plate~2. 10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)~3. 25g/d milk powder (skimmed and calcium added)~4. Leaflet content (same as control)
Study: NCT04055363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMO-supplemented infant formula
Description: Starter Infant Formula supplemented with 1.5g/L of Human Milk Oligosaccharides
Study: NCT00816959

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-mabHDI and ABVD
Description: The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.~Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABVD
Description: The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
Study: NCT04208659

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-administration of auricular acupuncture without prosthesis
Description: Participants will insert semi-permanent acupuncture needles in their ears without the guidance of a prosthesis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Self-administration of auricular acupuncture with prosthesis
Description: The same participants who previous self-administered a standardized auricular acupuncture will be given custom-molded prostheses midway through the study to assess how much the prostheses facilitate insertion.
Study: NCT04842110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: eonTM FR 1064 nm device
Description: The subject treatment area - abdomen, was treated with the 1064 nm wavelength laser.
Study: NCT01645306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revacept
Description: single intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Revacept
Description: single intravenous injection
Study: NCT02296216

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gamma Knife radiosurgery
Description: To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
Study: NCT01817920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: integrated multidisciplinary fall prevention program
Study: NCT00900692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynasplint
Description: Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen
Study: NCT02567708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 DPI
Description: GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DPI
Description: Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
Study: NCT02807610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inj Etomidate
Description: Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inj Etomidate
Description: Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0'.2mg kg-1 and IV Fentanyl 2ug kg-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection Propofol
Description: Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Propofol
Description: After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
Study: NCT04470947

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation functional drug screening
Description: High-throughput image based in-vitro drug screening on primary patient tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation functional drug screening
Description: High-throughput image based in-vitro drug screening on primary patient tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Next generation functional drug screening
Description: High-throughput image based in-vitro drug screening on primary patient tumor cells

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive genomic profiling
Description: Comprehensive targeted profiling of genetic aberrations on primary patient tumor material

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive genomic profiling
Description: Comprehensive targeted profiling of genetic aberrations on primary patient tumor material

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive genomic profiling
Description: Comprehensive targeted profiling of genetic aberrations on primary patient tumor material
Study: NCT01983423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endometrial Biopsy
Description: An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
Study: NCT02033447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Nanoparticle Injection
Study: NCT01647945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level < 2 ng/ml
Description: FK506 goal trough blood level \< 2 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level 2-3 ng/ml
Description: FK506 goal trough blood level 2-3 ng/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506 level 3-5 ng/ml
Description: FK506 goal trough blood level 3-5 ng/ml
Study: NCT01445327

Intervention type: OTHER
Intervention: Specimen collection
Study: NCT01035268

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fatty tissue transfer
Description: It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
Study: NCT00798252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivanib alaninate
Description: Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
Study: NCT02883036

Intervention type: OTHER
Intervention: blood sampling
Description: sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro

Intervention type: OTHER
Intervention: blood sampling
Description: sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
Study: NCT00625300

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial stimulation (r-TMS)
Description: Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial stimulation
Description: Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
Study: NCT00208247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral psychotherapy
Study: NCT01335347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Description: adenovirus with the dsRNA adjuvant, dried and put into capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Description: adenovirus with the dsRNA adjuvant, dried and put into capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ND1.1
Description: adenovirus with the dsRNA adjuvant, dried and put into capsules

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Capsules of the same size and shape as experimental groups
Study: NCT03819634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inset II with Lantern Technology
Description: Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure. The infusion set will be used with their usual insulin pump.
Study: NCT01423110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BYM338

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02900664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMT212
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMT212
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMT212
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Tablets
Study: NCT03732222

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching the diaphragm muscle
Description: Place the hands on the last costal cartilages and maintain the ascent of the ribs in the expiration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impulse technique in rotation of cervical level 3 and 4
Description: head to double chin position and then placed with neutral flexo-extension until focusing on the level of manipulation, ipsilateral lateral flexion and contralateral rotation approximately 45 degrees.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined technique of diaphragm muscle stretch and cervical rotation impulse technique level 3 and 4
Description: The same initial position, hand placement and technique guidelines will be used, cited in each of the techniques performed in the intervention 1 group and the intervention 2 group.
Study: NCT03632070

Intervention type: BEHAVIORAL
Intervention: Data acquisition of functional abilities
Description: MRI data, motor evoked potentials, and behavior data acquisition
Study: NCT04270695

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs which may cause to at least 60% restriction of blood flow detected by Power Doppler ultrasonography. All participants are instructed to perform abdominal draw-in maneuver.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: sham blood flow restriction
Description: an inflatable cuff (14 cm in width \* 84 cm in length) is warped around abdominal muscles below ribs without inflation. All participants are instructed to perform abdominal draw-in maneuver.
Study: NCT04035122

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Treatment
Description: The Lokomat is a robotic device, consisting of a powered gait orthosis with integrated computer-controlled linear actuators at each hip and knee joint, a body weight support, and a treadmill. During the Lokomat training, the patients completed at least 30 min of treatment session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: The standard physical treatment program consisted of general conditioning exercises, including warming up (e.g. calf, shoulder, and hand passive range of motion exercises), lower and upper extremity strengthening, postural control exercises. During the conventional training, the patients completed at least 30 min of treatment session.